Altimmune, Inc. announced positive topline results from its Phase 2b IMPACT trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH)....

CRISPR Therapeutics announced updates on its in vivo cardiovascular disease programs, including new Phase 1 data for CTX310 targeting...

Pliant Therapeutics has halted the development of bexotegrast for idiopathic pulmonary fibrosis (IPF) after a Phase 2b/3 trial, BEACON-IPF,...

HCW Biologics has developed second-generation, multi-specific T-cell engagers targeting solid tumors, particularly pancreatic cancer, using its proprietary TRBC platform....

Tango Therapeutics has initiated a Phase 1/2 trial evaluating TNG462, a PRMT5 inhibitor, in combination with Revolution Medicines’ RAS...

Glucotrack, Inc. announced positive results from its first-in-human clinical study of its implantable continuous blood glucose monitor (CBGM). The...

Amneal Pharmaceuticals announced positive topline results from a Phase 3 trial of ADL-018, a biosimilar to XOLAIR® (omalizumab), developed...

Assembly Biosciences announced positive topline results from a Phase 1b study of ABI-4334, a next-generation capsid assembly modulator (CAM),...

Corvus Pharmaceuticals‘ partner in China, Angel Pharma, has received approval from the China National Medical Products Administration (NMPA) to...

Alvotech, Kashiv Biosciences, and Advanz Pharma announced positive topline results from a phase 3 study of AVT23 (ADL-018), a...